THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Khobragade A, Bhate S, Ramaiah V, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. *Lancet* 2022; **399:** 1313–21.

Table 1: Summary of Treatment Emergent Adverse Events (Age 12-17) (Safety Population)

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	Dose II (N1=330) n(%)E	Dose III (N1=210) n(%)E	Dose I (N2=487) n(%)E	Dose II (N2=363) n(%)E	Dose III (N2=248) n(%)E	Dose I (N3=934) n(%)E	Dose II (N3=693) n(%)E	Dose III (N3=458) n(%)E
.									
Solicited Adverse Events									
Adverse Events									
Subject with any TEAE	14 (3.13) 23	3 (0.91) 3	-	7 (1.44) 16	3 (0.83) 4	2 (0.81) 3	21 (2.25) 39	6 (0.87) 7	2 (0.44) 3
Adverse Event Grade									
Mild	14 (100.00) 23	3 (100.00) 3	-	7 (100.00) 16	1 (33.33) 4	2 (100.00) 3	21 (100.00) 39	4 (66.67) 7	2 (100.00) 3
Causality									
Unrelated	1 (7.14) 2	-	-	-	-	-	1 (4.76) 2	-	-
Possibly related	-	-	-	2 (28.57) 2	-	-	2 (9.52) 2	-	-
Probably related	-	-	-	-	0 (0.00) 1	-	-	0 (0.00) 1	-
Definitely related	13 (92.86) 21	3 (100.00) 3	-	5 (71.43) 14	1 (33.33) 3	2 (100.00) 3	18 (85.71) 35	4 (66.67) 6	2 (100.00) 3
Action Taken									
None	9 (64.29) 17	3 (100.00) 3		7 (100.00) 16	1 (33.33) 4	2 (100.00) 3	16 (76.19) 33	4 (66.67) 7	2 (100.00) 3
Other	5 (35.71) 6	-	-	-	-	-	5 (23.81) 6	-	-
TEAE by outcome									
Recovered /Resolved	14 (100.00) 23	3 (100.00) 3	-	7 (100.00) 16	1 (33.33) 4	2 (100.00) 3	21 (100.00) 39	4 (66.67) 7	2 (100.00) 3
Unsolicited Adverse Events									
Adverse Events									
Subject with any TEAE	1 (0.22) 2	1 (0.30) 4	-	2 (0.41) 5	1 (0.28) 1	3 (1.21) 6	3 (0.32) 7	2 (0.29) 5	3 (0.66) 6
Adverse Event Grade									
Mild	1 (100.00) 2	1 (100.00) 4	-	2 (100.00) 5	1 (100.00) 1	3 (100.00) 6	3 (100.00) 7	2 (100.00) 5	3 (100.00) 6
Causality									
Unrelated	1 (100.00) 2	1 (100.00) 4		2 (100.00) 5	1 (100.00) 1	2 (66.67) 5	3 (100.00) 7	2 (100.00) 5	2 (66.67) 5
Possibly related	-	-	-	-	-	1 (33.33) 1	-	-	1 (33.33) 1
Action Taken									
None	1 (100.00) 2	1 (100.00) 4	-	2 (100.00) 5	-	2 (66.67) 5	3 (100.00) 7	1 (50.00) 4	2 (66.67) 5
Drug Withdrawn	-	-	-	-	1 (100.00) 1	-	-	1 (50.00) 1	-
Other	-	-	-	-	-	1 (33.33) 1	-	-	1 (33.33) 1
TEAE by outcome									
Recovered /Resolved	1 (100.00) 2	1 (100.00) 4	-	2 (100.00) 5	1 (100.00) 1	3 (100.00) 6	3 (100.00) 7	2 (100.00) 5	3 (100.00) 6

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE.

-TEAE are those adverse events which occurred after first dose of study medication.

-N1=Number of Subject at dose Dose I . N2=Number of Subject at dose Dose II .N3=Number of Subject at dose Dose III .

-Percentages for the 'Subject with any AE' and 'Subject with any serious AE' rows are based on the total number of subjects as per Dose
-Percentages for the Adverse event grade, Causality, Action Taken and outcome rows are based on the total number of subjects with any TEAE
-n’s in the Adverse event grade, Causality, Action Taken and outcome rows is based on the total number of Subjects With any TEAE.

Table 2: Summary of Treatment Emergent Adverse Events (Age>60 years) (Safety Population)

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	Dose II (N1=885) n(%)E	Dose III (N1=869) n(%)E	Dose I (N2=923) n(%)E	Dose II (N2=878) n(%)E	Dose III (N2=863) n(%)E	Dose I (N3=1847) n(%)E	Dose II (N3=1763) n(%)E	Dose III (N3=1732) n(%)E
Solicited Adverse Events									
Adverse Events									
Subject with any TEAE	7 (0.76) 11	10 (1.13) 11	14 (1.61) 14	18 (1.95) 24	13 (1.48) 13	10 (1.16) 10	25 (1.35) 35	23 (1.30) 24	24 (1.39) 24
Adverse Event Grade									
Mild	7 (100.00) 11	7 (70.00) 9	12 (85.71) 12	17 (94.44) 24	9 (69.23) 11	10 (100.00) 10	24 (96.00) 35	16 (69.57) 20	22 (91.67) 22
Moderate	-	1 (10.00) 2	2 (14.29) 2	-	1 (7.69) 2	-	-	2 (8.70) 4	2 (8.33) 2
Causality									
Unrelated	-	-	1 (7.14) 1	-	-	1 (10.00) 1	-	-	2 (8.33) 2
Possibly related	3 (42.86) 5	1 (10.00) 1	1 (7.14) 1	4 (22.22) 7	4 (30.77) 4	1 (10.00) 1	7 (28.00) 12	5 (21.74) 5	2 (8.33) 2
Probably related	2 (28.57) 4	6 (60.00) 8	9 (64.29) 9	3 (16.67) 7	2 (15.38) 4	4 (40.00) 4	5 (20.00) 11	8 (34.78) 12	13 (54.17) 13
Definitely related	2 (28.57) 2	-	-	10 (55.56) 10	2 (15.38) 2	2 (20.00) 2	12 (48.00) 12	2 (8.70) 2	2 (8.33) 2
Unknown	-	1 (10.00) 2	3 (21.43) 3	-	2 (15.38) 3	2 (20.00) 2	-	3 (13.04) 5	5 (20.83) 5
Action Taken									
None	6 (85.71) 10	7 (70.00) 10	13 (92.86) 13	17 (94.44) 24	9 (69.23) 12	9 (90.00) 9	23 (92.00) 34	16 (69.57) 22	22 (91.67) 22
Non-drug treatment required	1 (14.29) 1	-	-	-	-	-	1 (4.00) 1	-	-
Other	-	1 (10.00) 1	1 (7.14) 1	-	1 (7.69) 1	1 (10.00) 1	-	2 (8.70) 2	2 (8.33) 2
TEAE by outcome									

Recovered /Resolved	7 (100.00) 11	8 (80.00) 11	14 (100.00) 14	16 (88.89) 22	10 (76.92) 13	10 (100.00) 10	23 (92.00) 33	18 (78.26) 24	24 (100.00) 24
Recovered/Resolved with Sequelae	-	-	-	1 (5.56) 2	-	-	1 (4.00) 2	-	-
Unsolicited Adverse Events									
Adverse Events									
Subject with any TEAE	1 (0.11) 1	1 (0.11) 3	15 (1.73) 29	3 (0.33) 8	-	16 (1.85) 22	4 (0.22) 9	1 (0.06) 3	31 (1.79) 51
Subject with any serious TEAE	-	-	1 (0.12) 1	-	-	-	-	-	1 (0.06) 1
Adverse Event Grade									
Mild	1 (100.00) 1	1 (100.00) 3	14 (93.33) 23	3 (100.00) 8	-	15 (93.75) 20	4 (100.00) 9	1 (100.00) 3	29 (93.55) 43
Moderate	-	-	1 (6.67) 6	-	-	1 (6.25) 2	-	-	2 (6.45) 8
Causality									
Unrelated	1 (100.00) 1	1 (100.00) 3	8 (53.33) 21	3 (100.00) 8	-	11 (68.75) 17	4 (100.00) 9	1 (100.00) 3	19 (61.29) 38
Possibly related	-	-	5 (33.33) 5	-	-	5 (31.25) 5	-	-	10 (32.26) 10
Definitely related	-	-	1 (6.67) 2	-	-	-	-	-	1 (3.23) 2
Unknown	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Action Taken									
None	1 (100.00) 1	1 (100.00) 3	10 (66.67) 19	3 (100.00) 8	-	11 (68.75) 17	4 (100.00) 9	1 (100.00) 3	21 (67.74) 36
Non-drug treatment required	-	-	3 (20.00) 7	-	-	2 (12.50) 2	-	-	5 (16.13) 9
Hospitalization/prolonged hospitalization	-	-	0 (0.00) 1	-	-	-	-	-	0 (0.00) 1
Other	-	-	2 (13.33) 2	-	-	3 (18.75) 3	-	-	5 (16.13) 5
TEAE by outcome									
Recovered /Resolved	-	1 (100.00) 3	15 (100.00) 29	3 (100.00) 8	-	15 (93.75) 21	3 (75.00) 8	1 (100.00) 3	30 (96.77) 50

Recovered/Resolved with Sequelae	1 (100.00) 1	-	-	-	-	1 (6.25) 1	1 (25.00) 1	-	1 (3.23) 1

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE..
-TEAE are those adverse events which occurred after first dose of study medication.
-N1=Number of Subject at dose Dose I . N2=Number of Subject at dose Dose II .N3=Number of Subject at dose Dose III .
-Percentages for the 'Subject with any AE' and 'Subject with any serious AE' rows are based on the total number of subjects as per Dose
-Percentages for the Adverse event grade, Causality, Action Taken and outcome rows are based on the total number of subjects with any TEAE
-n's in the Adverse event grade, Causality, Action Taken and outcome rows is based on the total number of Subjects With any TEAE.

Table 3 Summary of Treatment Emergent Adverse Events (Comorbid subjects) (Safety Population)

	ZyCoV-D (N=709)			**Placebo (N=740)**			**Overall (N=1449)**		
	Dose I (N1=709) n(%)E	**Dose II (N1=688) n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Solicited Adverse Events									
Adverse Events									
Subject with any TEAE	11 (1.55) 20	3 (0.44) 3	8 (1.22) 9	22 (2.97) 50	11 (1.54) 13	7 (1.02) 7	33 (2.28) 70	14 (1.00) 16	15 (1.12) 16
Adverse Event Grade									
Mild	10 (90.91) 19	2 (66.67) 2	8 (100.00) 9	17 (77.27) 49	9 (81.82) 11	7 (100.00) 7	27 (81.82) 68	11 (78.57) 13	15 (100.00) 16
Moderate	1 (9.09) 1	1 (33.33) 1	-	1 (4.55) 1	1 (9.09) 2	-	2 (6.06) 2	2 (14.29) 3	-
Causality									
Unrelated	-	-	1 (12.50) 1	-	-	3 (42.86) 3	-	-	4 (26.67) 4
Possibly related	5 (45.45) 8	1 (33.33) 1	2 (25.00) 2	5 (22.73) 11	6 (54.55) 7	1 (14.29) 1	10 (30.30) 19	7 (50.00) 8	3 (20.00) 3
Probably related	4 (36.36) 10	-	3 (37.50) 4	8 (36.36) 32	-	1 (14.29) 1	12 (36.36) 42	-	4 (26.67) 5
Definitely related	2 (18.18) 2	1 (33.33) 1	2 (25.00) 2	5 (22.73) 7	2 (18.18) 2	1 (14.29) 1	7 (21.21) 9	3 (21.43) 3	3 (20.00) 3
Unknown	-	1 (33.33) 1	-	-	2 (18.18) 4	1 (14.29) 1	-	3 (21.43) 5	1 (6.67) 1
Action Taken									

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688) n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
None	10 (90.91) 19	3 (100.00) 3	6 (75.00) 7	16 (72.73) 48	7 (63.64) 8	6 (85.71) 6	26 (78.79) 67	10 (71.43) 11	12 (80.00) 13
Non-drug treatment required	-	-	1 (12.50) 1	1 (4.55) 1	-	-	1 (3.03) 1	-	1 (6.67) 1
Diagnostic or clinical test(s) conducted	-	-	-	-	1 (9.09) 2	-	-	1 (7.14) 2	-
Other	1 (9.09) 1	-	1 (12.50) 1	1 (4.55) 1	2 (18.18) 3	1 (14.29) 1	2 (6.06) 2	2 (14.29) 3	2 (13.33) 2
TEAE by outcome									
Recovered /Resolved	11 (100.00) 20	3 (100.00) 3	8 (100.00) 9	17 (77.27) 48	10 (90.91) 13	6 (85.71) 6	28 (84.85) 68	13 (92.86) 16	14 (93.33) 15
Recovered/Resolved with Sequelae	-	-	-	1 (4.55) 2	-	1 (14.29) 1	1 (3.03) 2	-	1 (6.67) 1
Unsolicited Adverse Events									
Adverse Events									
Subject with any TEAE	2 (0.28) 4	6 (0.87) 18	20 (3.04) 39	3 (0.41) 8	3 (0.42) 6	21 (3.07) 38	5 (0.35) 12	9 (0.64) 24	41 (3.06) 77
Subject with any serious TEAE	-	-	1 (0.15) 1	1 (0.14) 1	-	1 (0.15) 1	1 (0.07) 1	-	2 (0.15) 2
Adverse Event Grade									
Mild	1 (50.00) 4	1 (16.67) 18	14 (70.00) 30	3 (100.00) 6	0 (0.00) 6	15 (71.43) 35	4 (80.00) 10	1 (11.11) 24	29 (70.73) 65
Moderate	-	-	1 (5.00) 9	0 (0.00) 2	-	1 (4.76) 3	0 (0.00) 2	-	2 (4.88) 12
Causality									
Unrelated	2 (100.00) 1	6 (100.00) 3	9 (45.00) 21	3 (100.00) 8	2 (66.67) 0	11 (52.38) 17	5 (100.00) 9	8 (88.89) 3	20 (48.78) 38
Possibly related	-	-	6 (30.00) 5	-	-	8 (38.10) 5	-	-	14 (34.15) 10

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688) n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Probably related	-	-	1 (5.00) 0	-	-	-	-	-	1 (2.44) 0
Definitely related	-	-	2 (10.00) 2	-	-	-	-	-	2 (4.88) 2
Unknown	-	-	2 (10.00) 1	-	1 (33.33) 0	2 (9.52) 0	-	1 (11.11) 0	4 (9.76) 1
Action Taken									
None	1 (50.00) 2	4 (66.67) 13	13 (65.00) 22	2 (66.67) 4	1 (33.33) 1	15 (71.43) 21	3 (60.00) 6	5 (55.56) 14	28 (68.29) 43
Non-drug treatment required	-	1 (16.67) 2	2 (10.00) 7	-	-	2 (9.52) 7	-	1 (11.11) 2	4 (9.76) 14
Hospitalization/prolonged hospitalization	-	-	1 (5.00) 5	0 (0.00) 1	-	0 (0.00) 1	0 (0.00) 1	-	1 (2.44) 6
Diagnostic or clinical test(s) conducted	-	-	1 (5.00) 2	-	1 (33.33) 2	-	-	1 (11.11) 2	1 (2.44) 2
Drug Withdrawn	1 (50.00) 2	1 (16.67) 3	-	1 (33.33) 3	1 (33.33) 3	-	2 (40.00) 5	2 (22.22) 6	-
Other	-	-	3 (15.00) 3	-	-	4 (19.05) 9	-	-	7 (17.07) 12
TEAE by outcome									
Recovered /Resolved	2 (100.00) 4	6 (100.00) 18	20 (100.00) 39	3 (100.00) 8	3 (100.00) 6	21 (100.00) 38	5 (100.00) 12	9 (100.00) 24	41 (100.00) 77

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE..
-TEAE are those adverse events which occurred after first dose of study medication.
-N1=Number of Subject at dose Dose I . N2=Number of Subject at dose Dose II .N3=Number of Subject at dose Dose III .
-Percentages for the 'Subject with any AE' and 'Subject with any serious AE' rows are based on the total number of subjects as per Dose
-Percentages for the Adverse event grade, Causality, Action Taken and outcome rows are based on the total number of subjects with any TEAE
-n's in the Adverse event grade, Causality, Action Taken and outcome rows is based on the total number of Subjects With any TEAE.

Table 4 Summary of Treatment Emergent Adverse Events by System Organ Class and Preferred Term (Age 12-17 years, Safety Population)

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	**Dose II (N1=330)n(%)E**	**Dose III (N1=210) n(%)E**	**Dose I (N2=487) n(%)E**	**Dose II (N2=363) n(%)E**	**Dose III (N2=248) n(%)E**	**Dose I (N3=934) n(%)E**	**Dose II (N3=693) n(%)E**	**Dose III (N3=458) n(%)E**
Solicited Adverse Events									
Subject with any TEAE related to the IP	14 (3.13) 23	3 (0.91) 3	-	7 (1.44) 16	3 (0.83) 4	2 (0.81) 3	21 (2.25) 39	6 (0.87) 7	2 (0.44) 3
General disorders and administration site conditions	11 (78.57) 15	1 (33.33) 1	-	6 (85.71) 7	2 (66.67) 2	2 (100.00) 2	17 (80.95) 22	3 (50.00) 3	2 (100.00) 2
Fatigue	1 (7.14) 1	-	-	2 (28.57) 2	-	-	3 (14.29) 3	-	-
Injection site pain	10 (71.43) 11	1 (33.33) 1	-	5 (71.43) 5	1 (33.33) 1	2 (100.00) 2	15 (71.43) 16	2 (33.33) 2	2 (100.00) 2
Pyrexia	2 (14.29) 2	-	-	-	-	-	2 (9.52) 2	-	-
Swelling	1 (7.14) 1	-	-	-	1 (33.33) 1	-	1 (4.76) 1	1 (16.67) 1	-
Musculoskeletal and connective tissue disorders	-	-	-	2 (28.57) 4	-	-	2 (9.52) 4	-	-
Arthralgia	-	-	-	2 (28.57) 2	-	-	2 (9.52) 2	-	-
Myalgia	-	-	-	2 (28.57) 2	-	-	2 (9.52) 2	-	-
Nervous system disorders	3 (21.43) 3	-	-	1 (14.29) 1	1 (33.33) 1	-	4 (19.05) 4	1 (16.67) 1	-
Headache	3 (21.43) 3	-	-	1 (14.29) 1	1 (33.33) 1	-	4 (19.05) 4	1 (16.67) 1	-
Skin and subcutaneous tissue disorders	4 (28.57) 5	2 (66.67) 2	-	1 (14.29) 2	1 (33.33) 1	1 (50.00) 1	5 (23.81) 7	3 (50.00) 3	1 (50.00) 1
Erythema	2 (14.29) 2	2 (66.67) 2	-	-	1 (33.33) 1	1 (50.00) 1	2 (9.52) 2	3 (50.00) 3	1 (50.00) 1
Pruritus	2 (14.29) 3	-	-	1 (14.29) 2	-	-	3 (14.29) 5	-	-
Unsolicited Adverse Events									
Subject with any TEAE related to the IP	1 (0.22) 2	1 (0.30) 4	-	2 (0.41) 5	1 (0.28) 1	3 (1.21) 6	3 (0.32) 7	2 (0.29) 5	3 (0.66) 6

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	**Dose II (N1=330)n(%)E**	**Dose III (N1=210) n(%)E**	**Dose I (N2=487) n(%)E**	**Dose II (N2=363) n(%)E**	**Dose III (N2=248) n(%)E**	**Dose I (N3=934) n(%)E**	**Dose II (N3=693) n(%)E**	**Dose III (N3=458) n(%)E**
Gastrointestinal disorders	-	-	-	-	-	1 (33.33) 1	-	-	1 (33.33) 1
Mouth ulceration	-	-	-	-	-	1 (33.33) 1	-	-	1 (33.33) 1
General disorders and administration site conditions	1 (100.00) 1	1 (100.00) 2	-	1 (50.00) 2	1 (100.00) 1	1 (33.33) 2	2 (66.67) 3	2 (100.00) 3	1 (33.33) 2
Asthenia	-	1 (100.00) 1	-	-	-	-	-	1 (50.00) 1	-
Pain	-	-	-	1 (50.00) 1	-	1 (33.33) 1	1 (33.33) 1	-	1 (33.33) 1
Pyrexia	1 (100.00) 1	1 (100.00) 1	-	1 (50.00) 1	1 (100.00) 1	1 (33.33) 1	2 (66.67) 2	2 (100.00) 2	1 (33.33) 1
Respiratory, thoracic and mediastinal disorders	1 (100.00) 1	1 (100.00) 2	-	2 (100.00) 3	-	1 (33.33) 1	3 (100.00) 4	1 (50.00) 2	1 (33.33) 1
Cough	-	1 (100.00) 1	-	-	-	-	-	1 (50.00) 1	-
Oropharyngeal pain	1 (100.00) 1	-	-	1 (50.00) 1	-	1 (33.33) 1	2 (66.67) 2	-	1 (33.33) 1
Rhinorrhea	-	-	-	1 (50.00) 1	-	-	1 (33.33) 1	-	-
Sneezing	-	1 (100.00) 1	-	1 (50.00) 1	-	-	1 (33.33) 1	1 (50.00) 1	-

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE..

-TEAE are those adverse events which occurred after first dose of study medication.

-N1=Number of Subject at dose I N2=Number of Subject at dose II .N3=Number of Subject at dose III .

- IP = Investigational product.

-Percentage for the "Subject with at least one TEAE" were based on the total number of subjects per Dose.

--Percentage for the system organ class and preferred terms rows based on the total number of subjects with at least one TEAE.

System organ class are sorted by descending frequency in the overall treatment group preferred terms are sorted by descending frequency in the overall treatment group within system organ class Related includes possible and probable.

Adverse events were coded using MedDRA version 23. If a subject has multiple occurrences of an AE, the subject is presented only once in the respective subject count column (n) for the corresponding AE. Events are counted each time in the event (E) column

Table 5 Summary of Treatment Emergent Adverse Events by System Organ Class and Preferred Term (Age >60 years, Safety Population)

	ZyCoV-D (N=924)			**Placebo (N=923)**			**Overall (N=1847)**		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Solicited Adverse Events									
Subject with any TEAE related to the IP	7 (0.76) 11	10 (1.13) 11	14 (1.61) 14	18 (1.95) 24	13 (1.48) 13	10 (1.16) 10	25 (1.35) 35	23 (1.30) 24	24 (1.39) 24
Gastrointestinal disorders	-	-	1 (7.14) 1	-	1 (7.69) 1	-	-	1 (4.35) 1	1 (4.17) 1
Diarrhoea	-	-	-	-	1 (7.69) 1	-	-	1 (4.35) 1	-
Nausea	-	-	1 (7.14) 1	-	-	-	-	-	1 (4.17) 1
General disorders and administration site conditions	5 (71.43) 8	4 (40.00) 4	6 (42.86) 6	10 (55.56) 13	7 (53.85) 7	5 (50.00) 5	15 (60.00) 21	11 (47.83) 11	11 (45.83) 11
Fatigue	1 (14.29) 1	2 (20.00) 2	2 (14.29) 2	1 (5.56) 1	4 (30.77) 4	-	2 (8.00) 2	6 (26.09) 6	2 (8.33) 2
Injection site pain	5 (71.43) 5	1 (10.00) 1	1 (7.14) 1	7 (38.89) 7	2 (15.38) 2	2 (20.00) 2	12 (48.00) 12	3 (13.04) 3	3 (12.50) 3
Pyrexia	1 (14.29) 1	1 (10.00) 1	2 (14.29) 2	-	1 (7.69) 1	2 (20.00) 2	1 (4.00) 1	2 (8.70) 2	4 (16.67) 4
Swelling	1 (14.29) 1	-	1 (7.14) 1	5 (27.78) 5	-	1 (10.00) 1	6 (24.00) 6	-	2 (8.33) 2
Musculoskeletal and connective tissue disorders	1 (14.29) 1	-	1 (7.14) 1	3 (16.67) 3	1 (7.69) 1	2 (20.00) 2	4 (16.00) 4	1 (4.35) 1	3 (12.50) 3
Myalgia	1 (14.29) 1	-	1 (7.14) 1	3 (16.67) 3	1 (7.69) 1	2 (20.00) 2	4 (16.00) 4	1 (4.35) 1	3 (12.50) 3
Nervous system disorders	2 (28.57) 2	2 (20.00) 2	3 (21.43) 3	3 (16.67) 3	1 (7.69) 1	1 (10.00) 1	5 (20.00) 5	3 (13.04) 3	4 (16.67) 4
Headache	2 (28.57) 2	2 (20.00) 2	3 (21.43) 3	3 (16.67) 3	1 (7.69) 1	1 (10.00) 1	5 (20.00) 5	3 (13.04) 3	4 (16.67) 4

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Skin and subcutaneous tissue disorders	-	5 (50.00) 5	3 (21.43) 3	5 (27.78) 5	2 (15.38) 2	2 (20.00) 2	5 (20.00) 5	7 (30.43) 7	5 (20.83) 5
Erythema	-	4 (40.00) 4	2 (14.29) 2	4 (22.22) 4	-	1 (10.00) 1	4 (16.00) 4	4 (17.39) 4	3 (12.50) 3
Pruritus	-	1 (10.00) 1	1 (7.14) 1	1 (5.56) 1	2 (15.38) 2	1 (10.00) 1	1 (4.00) 1	3 (13.04) 3	2 (8.33) 2
Unsolicited Adverse Events									
Subject with any TEAE related to the IP	1 (0.11) 1	1 (0.11) 3	15 (1.73) 29	3 (0.33) 8	-	16 (1.85) 22	4 (0.22) 9	1 (0.06) 3	31 (1.79) 51
Gastrointestinal disorders	-	-	3 (20.00) 4	-	-	1 (6.25) 1	-	-	4 (12.90) 5
Abdominal pain	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Gastrooesophageal reflux disease	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Nausea	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Vomiting	-	-	1 (6.67) 1	-	-	1 (6.25) 1	-	-	2 (6.45) 2
General disorders and administration site conditions	1 (100.00) 1	1 (100.00) 1	6 (40.00) 8	2 (66.67) 2	-	7 (43.75) 7	3 (75.00) 3	1 (100.00) 1	13 (41.94) 15
Asthenia	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Pain	-	-	3 (20.00) 3	-	-	-	-	-	3 (9.68) 3
Pyrexia	1 (100.00) 1	1 (100.00) 1	4 (26.67) 4	2 (66.67) 2	-	7 (43.75) 7	3 (75.00) 3	1 (100.00) 1	11 (35.48) 11
Infections and infestations	-	1 (100.00) 1	2 (13.33) 2	1 (33.33) 1	-	3 (18.75) 3	1 (25.00) 1	1 (100.00) 1	5 (16.13) 5

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Nasopharyngitis	-	1 (100.00) 1	2 (13.33) 2	1 (33.33) 1	-	3 (18.75) 3	1 (25.00) 1	1 (100.00) 1	5 (16.13) 5
Investigations	-	-	1 (6.67) 5	-	-	-	-	-	1 (3.23) 5
Blood creatinine increased	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Blood glucose increased	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Blood pressure systolic increased	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Blood sodium increased	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Full blood count increased	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Musculoskeletal and connective tissue disorders	-	-	1 (6.67) 1	-	-	1 (6.25) 1	-	-	2 (6.45) 2
Myalgia	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Pain in extremity	-	-	-	-	-	1 (6.25) 1	-	-	1 (3.23) 1
Nervous system disorders	-	-	2 (13.33) 2	3 (100.00) 4	-	4 (25.00) 4	3 (75.00) 4	-	6 (19.35) 6
Ageusia	-	-	-	1 (33.33) 1	-	-	1 (25.00) 1	-	-
Cerebral infarction	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1
Headache	-	-	1 (6.67) 1	3 (100.00) 3	-	4 (25.00) 4	3 (75.00) 3	-	5 (16.13) 5
Respiratory, thoracic and mediastinal disorders	-	1 (100.00) 1	6 (40.00) 7	1 (33.33) 1	-	6 (37.50) 6	1 (25.00) 1	1 (100.00) 1	12 (38.71) 13
Cough	-	1 (100.00) 1	4 (26.67) 4	-	-	4 (25.00) 4	-	1 (100.00) 1	8 (25.81) 8
Nasal dryness	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Oropharyngeal pain	-	-	1 (6.67) 1	1 (33.33) 1	-	2 (12.50) 2	1 (25.00) 1	-	3 (9.68) 3
Rhinorrhea	-	-	1 (6.67) 1	-	-	-	-	-	1 (3.23) 1

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE..

-TEAE are those adverse events which occurred after first dose of study medication.

-N1=Number of Subject at dose I . N2=Number of Subject at dose II .N3=Number of Subject at dose III .

- IP = Investigational product.

-Percentage for the "Subject with at least one TEAE" were based on the total number of subjects per Dose.

--Percentage for the system organ class and preferred terms rows based on the total number of subjects with at least one TEAE.

System organ class are sorted by descending frequency in the overall treatment group preferred terms are sorted by descending frequency in the overall treatment group within system organ class Related includes possible and probable.

Adverse events were coded using MedDRA version 23. If a subject has multiple occurrences of an AE, the subject is presented only once in the respective subject count column (n) for the corresponding AE. Events are counted each time in the event (E) column

Table 6 Summary of Treatment Emergent Adverse Events by System Organ Class and Preferred Term (Comorbid Subjects, Safety Population)

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688)n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Solicited Adverse Events									
Subject with any TEAE related to the IP	11 (1.55) 20	3 (0.44) 3	8 (1.22) 9	22 (2.97) 50	11 (1.54) 13	7 (1.02) 7	33 (2.28) 70	14 (1.00) 16	15 (1.12) 16
Gastrointestinal disorders	1 (9.09) 1	-	-	1 (4.55) 1	1 (9.09) 1	-	2 (6.06) 2	1 (7.14) 1	-
Diarrhoea	1 (9.09) 1	-	-	1 (4.55) 1	1 (9.09) 1	-	2 (6.06) 2	1 (7.14) 1	-

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688)n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
General disorders and administration site conditions	7 (63.64) 12	1 (33.33) 1	3 (37.50) 3	18 (81.82) 27	9 (81.82) 9	3 (42.86) 3	25 (75.76) 39	10 (71.43) 10	6 (40.00) 6
Fatigue	1 (9.09) 1	1 (33.33) 1	-	1 (4.55) 1	4 (36.36) 4	-	2 (6.06) 2	5 (35.71) 5	-
Injection site pain	6 (54.55) 6	-	1 (12.50) 1	13 (59.09) 13	1 (9.09) 1	1 (14.29) 1	19 (57.58) 19	1 (7.14) 1	2 (13.33) 2
Pyrexia	2 (18.18) 2	-	2 (25.00) 2	3 (13.64) 3	4 (36.36) 4	2 (28.57) 2	5 (15.15) 5	4 (28.57) 4	4 (26.67) 4
Swelling	3 (27.27) 3	-		10 (45.45) 10	-	-	13 (39.39) 13	-	-
Musculoskeletal and connective tissue disorders	3 (27.27) 3	-	2 (25.00) 2	11 (50.00) 11	-	3 (42.86) 3	14 (42.42) 14	-	5 (33.33) 5
Arthralgia	-	-	1 (12.50) 1	1 (4.55) 1	-	-	1 (3.03) 1	-	1 (6.67) 1
Myalgia	3 (27.27) 3	-	1 (12.50) 1	10 (45.45) 10	-	3 (42.86) 3	13 (39.39) 13	-	4 (26.67) 4
Nervous system disorders	2 (18.18) 2	1 (33.33) 1	3 (37.50) 3	3 (13.64) 3	2 (18.18) 2	1 (14.29) 1	5 (15.15) 5	3 (21.43) 3	4 (26.67) 4
Headache	2 (18.18) 2	1 (33.33) 1	3 (37.50) 3	3 (13.64) 3	2 (18.18) 2	1 (14.29) 1	5 (15.15) 5	3 (21.43) 3	4 (26.67) 4
Skin and subcutaneous tissue disorders	1 (9.09) 1	1 (33.33) 1	1 (12.50) 1	7 (31.82) 8	1 (9.09) 1	-	8 (24.24) 9	2 (14.29) 2	1 (6.67) 1
Erythema	1 (9.09) 1	1 (33.33) 1	1 (12.50) 1	5 (22.73) 5	-	-	6 (18.18) 6	1 (7.14) 1	1 (6.67) 1
Pruritus	-	-	-	3 (13.64) 3	1 (9.09) 1	-	3 (9.09) 3	1 (7.14) 1	-
Unsolicited Adverse Events									

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688)n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Subject with any TEAE related to the IP	2 (0.28) 4	6 (0.87) 18	19 (2.89) 38	3 (0.41) 8	3 (0.42) 6	21 (3.07) 38	5 (0.35) 12	9 (0.64) 24	40 (2.98) 76
Gastrointestinal disorders	-	-	2 (10.53) 2	-	-	4 (19.05) 5	-	-	6 (15.00) 7
Abdominal distension	-	-	-	-	-	1 (4.76) 1	-	-	1 (2.50) 1
Abdominal pain	-	-	2 (10.53) 2	-	-	1 (4.76) 1	-	-	3 (7.50) 3
Gastrooesophageal reflux disease	-	-	-	-	-	1 (4.76) 1	-	-	1 (2.50) 1
Vomiting	-	-	-	-	-	2 (9.52) 2	-	-	2 (5.00) 2
General disorders and administration site conditions	2 (100.00) 2	5 (83.33) 8	8 (42.11) 11	1 (33.33) 1	1 (33.33) 2	8 (38.10) 9	3 (60.00) 3	6 (66.67) 10	16 (40.00) 20
Asthenia	-	2 (33.33) 2	2 (10.53) 2	1 (33.33) 1	-	-	1 (20.00) 1	2 (22.22) 2	2 (5.00) 2
Fatigue	-	-	-	-	-	2 (9.52) 2	-	-	2 (5.00) 2
Pain	-	3 (50.00) 3	4 (21.05) 4	-	1 (33.33) 1	1 (4.76) 1	-	4 (44.44) 4	5 (12.50) 5
Pyrexia	2 (100.00) 2	3 (50.00) 3	5 (26.32) 5	-	1 (33.33) 1	5 (23.81) 6	2 (40.00) 2	4 (44.44) 4	10 (25.00) 11
Infections and infestations	-	-	1 (5.26) 1	-	-	3 (14.29) 3	-	-	4 (10.00) 4
Nasopharyngitis	-	-	1 (5.26) 1	-	-	3 (14.29) 3	-	-	4 (10.00) 4
Investigations	-	-	1 (5.26) 5	-	-	-	-	-	1 (2.50) 5
Blood creatinine increased	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688)n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Blood glucose increased	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Blood pressure systolic increased	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Blood sodium increased	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Full blood count increased	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Musculoskeletal and connective tissue disorders	-	-	-	-	-	4 (19.05) 4	-	-	4 (10.00) 4
Arthralgia	-	-	-	-	-	2 (9.52) 2	-	-	2 (5.00) 2
Myalgia	-	-	-	-	-	2 (9.52) 2	-	-	2 (5.00) 2
Nervous system disorders	-	3 (50.00) 3	7 (36.84) 7	3 (100.00) 4	-	4 (19.05) 5	3 (60.00) 4	3 (33.33) 3	11 (27.50) 12
Ageusia	-	-	-	-	-	2 (9.52) 2	-	-	2 (5.00) 2
Anosmia	-	-	1 (5.26) 1	-	-	1 (4.76) 1	-	-	2 (5.00) 2
Cerebral infarction	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Cerebrovascular accident	-	-	-	1 (33.33) 1	-	-	1 (20.00) 1	-	-
Dizziness	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Headache	-	3 (50.00) 3	4 (21.05) 4	2 (66.67) 2		2 (9.52) 2	2 (40.00) 2	3 (33.33) 3	6 (15.00) 6
Somnolence	-	-	-	1 (33.33) 1	-	-	1 (20.00) 1	-	-
Respiratory, thoracic and mediastinal disorders	1 (50.00) 1	4 (66.67) 5	9 (47.37) 10	2 (66.67) 2	3 (100.00) 4	9 (42.86) 10	3 (60.00) 3	7 (77.78) 9	18 (45.00) 20
Cough	1 (50.00) 1	3 (50.00) 3	5 (26.32) 5	-	2 (66.67) 2	5 (23.81) 5	1 (20.00) 1	5 (55.56) 5	10 (25.00) 10
Hypoxia	-	-	-	-	-	1 (4.76) 1	-	-	1 (2.50) 1

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688)n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Nasal dryness	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Oropharyngeal pain	-	1 (16.67) 1	3 (15.79) 3	2 (66.67) 2	2 (66.67) 2	4 (19.05) 4	2 (40.00) 2	3 (33.33) 3	7 (17.50) 7
Rhinorrhea	-	-	1 (5.26) 1	-	-	-	-	-	1 (2.50) 1
Sneezing	-	1 (16.67) 1	-	-	-	-	-	1 (11.11) 1	-
Vascular disorders	-	-	-	1 (33.33) 1	-	-	1 (20.00) 1	-	-
Hypertension	-	-	-	1 (33.33) 1	-	-	1 (20.00) 1	-	-

-TEAE = treatment-emergent adverse event; N = number of Subjects at risk; E = number of TEAE.

-TEAE are those adverse events which occurred after first dose of study medication.

-N1=Number of Subject at dose I . N2=Number of Subject at dose II .N3=Number of Subject at dose III.

- IP = Investigational product.

-Percentage for the "Subject with at least one TEAE" were based on the total number of subjects per Dose.

--Percentage for the system organ class and preferred terms rows based on the total number of subjects with at least one TEAE.

System organ class are sorted by descending frequency in the overall treatment group preferred terms are sorted by descending frequency in the overall treatment group within system organ class Related includes possible and probable.

Adverse events were coded using MedDRA version 23 . If a subject has multiple occurrences of an AE, the subject is presented only once in the respective subject count column (n) for the corresponding AE. Events are counted each time in the event (E) column

Table 7 Summary of Solicited Local Adverse Events and Solicited Systemic Adverse Events (Age: 12-17 years, Safety Population)

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	**Dose II (N1=330) n(%)E**	**Dose III (N1=210) n(%)E**	**Dose I (N2=487) n(%)E**	**Dose II (N2=363) n(%)E**	**Dose III (N2=248) n(%)E**	**Dose I (N3=934) n(%)E**	**Dose II (N3=693) n(%)E**	**Dose III (N3=458) n(%)E**
Solicited Local Adverse Events									

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	**Dose II (N1=330) n(%)E**	**Dose III (N1=210) n(%)E**	**Dose I (N2=487) n(%)E**	**Dose II (N2=363) n(%)E**	**Dose III (N2=248) n(%)E**	**Dose I (N3=934) n(%)E**	**Dose II (N3=693) n(%)E**	**Dose III (N3=458) n(%)E**
Pain injection site	10(2.24) 11	1(0.30) 1	-	5(1.03) 5	1(0.28) 1	2(0.81) 2	15(1.61) 16	2(0.29) 2	2(0.44) 2
Mild	10(100) 11	1(100) 1	-	5(100) 5	1(100) 1	2(100) 2	15(100) 16	2(100) 2	2(100) 2
Redness	2(0.45) 2	2(0.61) 2	-	-	1(0.28) 1	1(0.40) 1	2(0.21) 2	3(0.43) 3	1(0.22) 1
Mild	2(100) 2	2(100) 2	-	-	1(100) 1	1(100) 1	2(100) 2	3(100) 3	1(100) 1
Swelling	1(0.22) 1	-	-	-	1(0.28) 1	-	1(0.11) 1	1(0.14) 1	-
Mild	1(100) 1	-	-		1(100) 1	-	1(100) 1	1(100) 1	-
Itching	2(0.45) 3	-	-	1(0.21) 2	-	-	3(0.32) 5	-	-
Mild	2(100) 3	-	-	1(100) 2	-	-	3(100) 5	-	-
Solicited Systemic Adverse Events									
Diarrhoea	-	-	-	-	-	-	-	-	-
Arthralgia	-	-	-	2(0.41) 2	-	-	2(0.21) 2	-	-
Mild	-	-	-	2(100) 2	-	-	2(100) 2	-	-
Muscle Pain	-	-	-	2(0.41) 2	-	-	2(0.21) 2	-	-
Mild	-	-	-	2(100) 2	-	-	2(100) 2	-	-
Headache	3(0.67) 3	-	-	2(0.41) 2	1(0.28) 1	-	5(0.54) 5	1(0.14) 1	-
Mild	3(100) 3	-	-	2(100) 2	1(100) 1	-	5(100) 5	1(100) 1	-
Nausea	-	-	-	-	-	-	-	-	-
Malaise	-	-	-	-	-	-	-	-	-
Fatigue	1(0.22) 1	-	-	3(0.62) 3	-	-	4(0.43) 4	-	-
Mild	1(100) 1	-	-	3(100) 3	-	-	4(100) 4	-	-
Fever	2(0.45) 2	-	-	-	-	-	2(0.21) 2	-	-

	ZyCoV-D (N=447)			Placebo (N=487)			Overall (N=934)		
	Dose I (N1=447) n(%)E	**Dose II (N1=330) n(%)E**	**Dose III (N1=210) n(%)E**	**Dose I (N2=487) n(%)E**	**Dose II (N2=363) n(%)E**	**Dose III (N2=248) n(%)E**	**Dose I (N3=934) n(%)E**	**Dose II (N3=693) n(%)E**	**Dose III (N3=458) n(%)E**
Mild	2(100) 2	-	-	-	-	-	2(100) 2	-	-
N = number of Subjects at risk; n=number Subjects with AE; E = number of AE. -N1=Number of Subject at dose I N2=Number of Subject at dose II .N3=Number of Subject at dose III .									

Table 8 Summary of Solicited Local Adverse Events and Solicited Systemic Adverse Events (Age >60 years, Safety Population)

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Solicited Local Adverse Events									
Pain injection site	5(0.54) 5	1(0.11) 1	1(0.12) 1	7(0.76) 7	2(0.23) 2	2(0.23) 2	12(0.65) 12	3(0.17) 3	3(0.17) 3
Mild	5(100) 5	1(100) 1	1(100) 1	7(100) 7	2(100) 2	2(100) 2	12(100) 12	3(100) 3	3(100) 3
Redness	-	4(0.45) 4	2(0.23) 2	4(0.43) 4	-	1(0.12) 1	4(0.22) 4	4(0.23) 4	3(0.17) 3
Mild	-	4(100) 4	2(100) 2	4(100) 4	-	1(100) 1	4(100) 4	4(100) 4	3(100) 3
Swelling	1(0.11) 1	-	1(0.12) 1	5(0.54) 5	-	1(0.12) 1	6(0.32) 6	-	2(0.12) 2
Mild	1(100) 1	-	1(100) 1	5(100) 5	-	1(100) 1	6(100) 6	-	2(100) 2
Itching	-	1(0.11) 1	1(0.12) 1	1(0.11) 1	2(0.23) 2	1(0.12) 1	1(0.05) 1	3(0.17) 3	2(0.12) 2
Mild	-	1(100) 1	-	1(100) 1	2(100) 2	1(100) 1	1(100) 1	3(100) 3	1(50.00) 1
Moderate	-	-	1(100) 1	-	-	-	-	-	1(50.00) 1
Solicited Systemic Adverse Events									
Diarrhoea	-	-	-	-	1(0.11) 1	-	-	1(0.06) 1	-

	ZyCoV-D (N=924)			Placebo (N=923)			Overall (N=1847)		
	Dose I (N1=924) n(%)E	**Dose II (N1=885) n(%)E**	**Dose III (N1=869) n(%)E**	**Dose I (N2=923) n(%)E**	**Dose II (N2=878) n(%)E**	**Dose III (N2=863) n(%)E**	**Dose I (N3=1847) n(%)E**	**Dose II (N3=1763) n(%)E**	**Dose III (N3=1732) n(%)E**
Moderate	-	-	-	-	1(100) 1	-	-	1(100) 1	-
Arthralgia	-	-	-	-	-	-	-	-	-
Muscle Pain	1(0.11) 1	-	1(0.12) 1	3(0.33) 3	1(0.11) 1	2(0.23) 2	4(0.22) 4	1(0.06) 1	3(0.17) 3
Mild	1(100) 1	-	1(100) 1	3(100) 3	1(100) 1	2(100) 2	4(100) 4	1(100) 1	3(100) 3
Headache	2(0.22) 2	2(0.23) 2	3(0.35) 3	3(0.33) 3	1(0.11) 1	1(0.12) 1	5(0.27) 5	3(0.17) 3	4(0.23) 4
Mild	2(100) 2	2(100) 2	3(100) 3	3(100) 3	1(100) 1	1(100) 1	5(100) 5	3(100) 3	4(100) 4
Nausea	-	-	1(0.12) 1	-	-	-	-	-	1(0.06) 1
Mild	-	-	1(100) 1	-	-	-	-	-	1(100) 1
Malaise	-	-	-	-	-	-	-	-	-
Fatigue	1(0.11) 1	2(0.23) 2	2(0.23) 2	1(0.11) 1	4(0.46) 4	-	2(0.11) 2	6(0.34) 6	2(0.12) 2
Mild	1(100) 1	-	1(50.00) 1	1(100) 1	3(75.00) 3	-	2(100) 2	3(50.00) 3	1(50.00) 1
Moderate	-	2(100) 2	1(50.00) 1	-	1(25.00) 1	-	-	3(50.00) 3	1(50.00) 1
Fever	1(0.11) 1	1(0.11) 1	2(0.23) 2	-	1(0.11) 1	2(0.23) 2	1(0.05) 1	2(0.11) 2	4(0.23) 4
Mild	1(100) 1	1(100) 1	2(100) 2	-	1(100) 1	2(100) 2	1(100) 1	2(100) 2	4(100) 4

N = number of Subjects at risk; n=numbr Subjects with AE; E = number of AE.

-N1=Number of Subject at dose Dose I . N2=Number of Subject at dose Dose II .N3=Number of Subject at dose Dose III .

Table 9 Summary of Solicited Local Adverse Events and Solicited Systemic Adverse Events (Co-morbid Subjects, Safety Population)

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688) n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Solicited Local Adverse Events									
Pain injection site	6(0.85) 6	-	1(0.15) 1	13(1.76) 13	1(0.14) 1	1(0.15) 1	19(1.31) 19	1(0.07) 1	2(0.15) 2
Mild	6(100) 6	-	1(100) 1	13(100) 13	1(100) 1	1(100) 1	19(100) 19	1(100) 1	2(100) 2
Redness	2(0.28) 2	1(0.15) 1	1(0.15) 1	5(0.68) 5	-	-	7(0.48) 7	1(0.07) 1	1(0.07) 1
Mild	2(100) 2	1(100) 1	1(100) 1	5(100) 5	-	-	7(100) 7	1(100) 1	1(100) 1
Swelling	3(0.42) 3	-	-	10(1.35) 10	-	-	13(0.90) 13	-	-
Mild	3(100) 3	-	-	10(100) 10	-	-	13(100) 13	-	-
Itching	-	-	-	3(0.41) 3	1(0.14) 1	-	3(0.21) 3	1(0.07) 1	-
Mild	-	-	-	3(100) 3	1(100) 1	-	3(100) 3	1(100) 1	-
Solicited Systemic Adverse Events									
Diarrhoea	1(0.14) 1	-	-	1(0.14) 1	1(0.14) 1	-	2(0.14) 2	1(0.07) 1	-
Mild	-	-	-	1(100) 1	-	-	1(50.00) 1	-	-
Moderate	1(100) 1	-	-	-	1(100) 1	-	1(50.00) 1	1(100) 1	-
Arthralgia	-	-	1(0.15) 1	1(0.14) 1	-	-	1(0.07) 1	-	1(0.07) 1
Mild	-	-	1(100) 1	1(100) 1	-	-	1(100) 1	-	1(100) 1
Muscle Pain	3(0.42) 3	-	1(0.15) 1	10(1.35) 10	-	3(0.44) 3	13(0.90) 13	-	4(0.30) 4
Mild	3(100) 3	-	1(100) 1	9(90.00) 9	-	3(100) 3	12(92.31) 12	-	4(100) 4
Moderate	-	-	-	1(10.00) 1	-	-	1(7.69) 1	-	-
Headache	2(0.28) 2	1(0.15) 1	3(0.46) 3	3(0.41) 3	2(0.28) 2	1(0.15) 1	5(0.35) 5	3(0.21) 3	4(0.30) 4
Mild	2(100) 2	1(100) 1	3(100) 3	3(100) 3	2(100) 2	1(100) 1	5(100) 5	3(100) 3	4(100) 4
Nausea	-	-	-	-	-	-	-	-	-

	ZyCoV-D (N=709)			Placebo (N=740)			Overall (N=1449)		
	Dose I (N1=709) n(%)E	**Dose II (N1=688) n(%)E**	**Dose III (N1=658) n(%)E**	**Dose I (N2=740) n(%)E**	**Dose II (N2=713) n(%)E**	**Dose III (N2=684) n(%)E**	**Dose I (N3=1449) n(%)E**	**Dose II (N3=1401) n(%)E**	**Dose III (N3=1342) n(%)E**
Malaise	-	-	-	-	-	-	-	-	-
Fatigue	1(0.14) 1	1(0.15) 1	-	1(0.14) 1	4(0.56) 4	-	2(0.14) 2	5(0.36) 5	-
Mild	1(100) 1	-		1(100) 1	3(75.00) 3	-	2(100) 2	3(60.00) 3	-
Moderate	-	1(100) 1	-	-	1(25.00) 1	-	-	2(40.00) 2	-
Fever	2(0.28) 2	-	2(0.30) 2	3(0.41) 3	4(0.56) 4	2(0.29) 2	5(0.35) 5	4(0.29) 4	4(0.30) 4
Mild	2(100) 2	-	2(100) 2	3(100) 3	4(100) 4	2(100) 2	5(100) 5	4(100) 4	4(100) 4

N = number of Subjects at risk; n=number Subjects with AE; E = number of AE.

-N1=Number of Subject at dose I. N2=Number of Subject at dose II. N3=Number of Subject at dose III.